Amersham's Ceretec used for Alzheimer's detection
This article was originally published in Clinica
Executive Summary
Latest results from a UK study show that brain scanning combined with functional imaging of blood flow using SPECT with Amersham International's technetium-99m agent, Ceretec, provides enhanced accuracy in diagnosing Alzheimer's disease. The technology, developed by the Oxford Project to Investigate Memory and Ageing (OPTIMA), is being used in hospitals in the UK, France, Germany, South Africa and Australia, Amersham's medical director, Dr Rhiannon Rowsell, told Clinica.
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.